...
首页> 外文期刊>Nano letters >Nanovectorization of TRAIL with Single Wall Carbon Nanotubes Enhances Tumor Cell Killing
【24h】

Nanovectorization of TRAIL with Single Wall Carbon Nanotubes Enhances Tumor Cell Killing

机译:单壁碳纳米管对TRAIL的纳米载体化增强了肿瘤细胞的杀伤力

获取原文
获取原文并翻译 | 示例

摘要

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2L) is a member of the tumor necrosis factor (TNF) superfamily. This type II transmembrane protein is able to bound specifically to cancer cell receptors (i.e., TRAIL-R1 (or DR4) and TRAIL-R2 (or DR5)) and to induce apoptosis without being toxic for healthy cells. Because membrane-bound TRAIL induces stronger receptor aggregation and apoptosis than soluble TRAIL, we proposed here to vectorize TRAIL using single-walled carbon nanotubes (SWCNTs) to mimic membrane TRAIL. Owing to their exceptional and revolutional properties, carbon nanotubes, especially SWCNTs, are used in a wide range of physical or, now, medical applications. Indeed due to their high mechanical resistance, their high flexibility and their hydrophobicity, SWCNTs are known to rapidly diffuse in an aqueous medium such as blood, opening the way of development of new drug nanovectors (or nanocarriers). Our TRAIL-based SWCNTs nanovectors proved to be more efficient than TRAIL alone death receptors in triggering cancer cell killing. These NPTs increased TRAIL pro-apoptotic potential by nearly 20-fold in different Human tumor cell lines including colorectal, nonsmall cell lung cancer, or hepatocarcinomas. We provide thus a proof-of-concept that TRAIL nanovector derivatives based on SWCNT may be useful to future nanomedicine therapies.
机译:肿瘤坏死因子相关的凋亡诱导配体(TRAIL或Apo2L)是肿瘤坏死因子(TNF)超家族的成员。这种II型跨膜蛋白能够与癌细胞受体(即TRAIL-R1(或DR4)和TRAIL-R2(或DR5))特异性结合,并诱导凋亡,而对健康细胞没有毒性。因为膜结合的TRAIL比可溶性TRAIL诱导更强的受体聚集和凋亡,所以我们在这里提出使用单壁碳纳米管(SWCNT)来模拟膜TRAIL,从而将TRAIL矢量化。由于其出色的性能和革命性的特性,碳纳米管,特别是SWCNT,被广泛用于物理或现在的医学应用中。实际上,由于其高的机械抵抗力,高的柔韧性和疏水性,SWCNT可以迅速在水性介质(例如血液)中扩散,从而开辟了新药物纳米载体(或纳米载体)的开发方式。我们证明,基于TRAIL的SWCNTs纳米载体在触发癌细胞杀伤方面比单独的TRAIL死亡受体更有效。这些NPT在包括结肠直肠癌,非小细胞肺癌或肝癌在内的不同人类肿瘤细胞系中将TRAIL的促凋亡潜力提高了近20倍。因此,我们提供了概念证明,即基于SWCNT的TRAIL纳米载体衍生物可能对未来的纳米药物治疗有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号